Use Caution/Monitor. Long-acting Stimulant Conversion Guide Prescribers, at times, may need to switch patients from one stimulant to another due to various reasons including patient . Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Use Caution/Monitor. Monitor BP. Monitor Closely (1)levalbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor BP. Use Caution/Monitor. Additive pressor effect. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. Monitor BP. Monitor Closely (1)pirbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Applies only to oral form of both agents. A Patient Handout is not currently available for this monograph. Other (see comment). Use Caution/Monitor. Ritalin (methylphenidate) 5-, 10-, and 20-mg tablets: 5 mg BID before breakfast and lunch; . In general, administer drugs at least 2 hr before or after sodium zirconium cyclosilicate. levalbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Optimal doses appear to be 1.2 mg/kg daily, given once daily or in two divided doses. Monitor Closely (1)aripiprazole increases toxicity of methylphenidate by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Potential for additive CNS stimulation. Use Caution/Monitor. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Monitor Closely (1)sufentanil SL, methylphenidate. Use Caution/Monitor. Monitor BP. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Use Caution/Monitor. Other (see comment). only. commonly, these are "non-preferred" brand drugs or specialty Use Caution/Monitor. Other (see comment). Risk of acute hypertensive episode. Monitor BP. Additive vasospasm; risk of hypertension. Avoid or Use Alternate Drug. Monitor Closely (1)methylphenidate will decrease the level or effect of telmisartan by pharmacodynamic antagonism. Risk of acute hypertensive episode. nortriptyline, methylphenidate. epinephrine racemic and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. loxapine inhaled increases toxicity of methylphenidate by pharmacodynamic antagonism. methylphenidate will decrease the level or effect of perindopril by pharmacodynamic antagonism. linezolid increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. armodafinil increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Tranylcypromine. Applies only to oral form of both agents. Comment: Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Interaction more likely in certain predisposed pts. Applies only to oral form of both agents. Monitor for decreased therapeutic effects of methylphenidate if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose decreased. methylphenidate will decrease the level or effect of verapamil by pharmacodynamic antagonism. Mechanism: unknown. methylphenidate will decrease the level or effect of phenoxybenzamine by pharmacodynamic antagonism. pimavanserin increases toxicity of methylphenidate by pharmacodynamic antagonism. Risk of acute hypertensive episode. Monitor BP. Use Caution/Monitor. prochlorperazine, methylphenidate. Contraindicated. Use Caution/Monitor. Risk of V tach, HTN. Methylphenidate may diminish antihypertensive effects. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. hydrocodone, methylphenidate. Methylphenidate may diminish antihypertensive effects. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Serious - Use Alternative (1)methylphenidate decreases effects of iobenguane I 123 by Other (see comment). Sympathomimetics can antagonize the activity of some antihypertensive agents. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Methylphenidate may diminish antihypertensive effects. Risk of acute hypertensive episode. Use Caution/Monitor. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. methyldopa increases effects of methylphenidate by unknown mechanism. Risk of acute hypertensive episode. Contraindicated. Methylphenidate may diminish antihypertensive effects. Mechanism: pharmacodynamic synergism. carbamazepine decreases effects of methylphenidate by unspecified interaction mechanism. methamphetamine increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Table 3. Monitor BP. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. only. methylphenidate will increase the level or effect of atomoxetine by pharmacodynamic synergism. Use Caution/Monitor. Mechanism: unknown. Minor/Significance Unknown. trimipramine, methylphenidate. Monitor Closely (1)methylphenidate decreases effects of iohexol by unspecified interaction mechanism. Monitor BP. Use Caution/Monitor. Interaction more likely in certain predisposed pts. Methylphenidate may diminish antihypertensive effects. Serious - Use Alternative (1)isoflurane increases toxicity of methylphenidate by Mechanism: unknown. Use Caution/Monitor. Use Caution/Monitor. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Monitor Closely (1)iloperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Risk of acute hypertensive episode. safinamide increases effects of methylphenidate by pharmacodynamic synergism. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Contraindicated. Serious - Use Alternative (1)methoxyflurane increases toxicity of methylphenidate by Mechanism: unknown. The generic drug name of Concerta is methylphenidate. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Use Caution/Monitor. prescription products. hydralazine, methylphenidate. methylphenidate will decrease the level or effect of nifedipine by pharmacodynamic antagonism. Monitor for hypertension with concomitant use. Closely monitor blood pressure with concomitant use of esketamine nasal with stimulants. Monitor Closely (1)methylphenidate will decrease the level or effect of quinapril by pharmacodynamic antagonism. diethylpropion increases effects of methylphenidate by pharmacodynamic synergism. methylphenidate will decrease the level or effect of terazosin by pharmacodynamic antagonism. only.fluphenazine increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. doxepin, methylphenidate. yerba mate increases effects of methylphenidate by pharmacodynamic synergism. Mechanism: unknown. Monitor Closely (1)dexmethylphenidate increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Use Caution/Monitor. Monitor Closely (1)methylphenidate decreases effects of iopamidol by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Potential for additive CNS stimulation. Other (see comment). Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Use Caution/Monitor. only.trifluoperazine increases toxicity of methylphenidate by pharmacodynamic antagonism. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Currently on methylphenidate 5 mg BID or . Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)methylphenidate will increase the level or effect of phenobarbital by unknown mechanism. Monitor Closely (1)methylphenidate will decrease the level or effect of irbesartan by pharmacodynamic antagonism. Monitor Closely (2)fluphenazine, methylphenidate. dopexamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Use Caution/Monitor. methylphenidate will decrease the level or effect of prazosin by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Monitor BP. Avoid or Use Alternate Drug. Risk of acute hypertensive episode. Either increases effects of the other by pharmacodynamic synergism. Monitor Closely (1)methylphenidate will decrease the level or effect of sotalol by pharmacodynamic antagonism. 10mg (Aptensio XR, Ritalin LA, Metadate CD), 20mg (Aptensio XR, Ritalin LA, Metadate CD), 30mg (Aptensio XR, Ritalin LA, Metadate CD), 40mg (Aptensio XR, Ritalin LA, Metadate CD), 60mg (Aptensio XR, Ritalin LA, Metadate CD), If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage, or, if necessary, discontinue drug, Periodically discontinue treatment to assess condition, If improvement not observed after appropriate dosage adjustment over a one-month period, discontinue treatment, Currently on methylphenidate 5 mg BID or TID: Start Concerta or Relexxii at 18 mg qAM, Currently on methylphenidate 10 mg BID or TID: Start Concerta or Relexxii at 36 mg qAM, Currently on methylphenidate 15 mg BID or TID: Start Concerta or Relexxii at 54 mg qAM, Currently on methylphenidate 20 mg BID or TID: Start Concerta or Relexxii at 72 mg qAM, Since renal clearance is not an important route of clearance, renal insufficiency is expected to have little effect on pharmacokinetics of methylphenidate ER tablets, \No experience with use in patients with hepatic insufficiency, Assess for presence of cardiac disease (eg, family history of sudden death or ventricular arrhythmia), Assess risk of abuse before prescribing and monitor for signs of abuse and dependence during therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate need for use, Adhansia XR: 25 mg PO qAM initially; may titrate up in increments of 10-15 mg at intervals of at least 5 days; dosages 70 mg/day associated with increased incidence of certain adverse reactions, Cotempla XR-ODT (oral disintegrating tablets): 17.3 mg PO qAM initially; may titrate upward weekly by 8.6-17.3 mg increments; not to exceed 51.8 mg/day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO BID 30-45 minutes before breakfast and lunch initially; may increase by 5-10 mg/day at weekly intervals; not to exceed 60 mg/day divided BID/TID, Methylin ER: May be given in place of immediate-release products once daily dose is titrated and the titrated 8-hr dosage corresponds to SR or ER tablet size; not to exceed 60 mg/day, Metadate CD, Ritalin LA: Initial, 20 mg PO qAM; may increase by 10 mg (Ritalin LA) or 10-20 mg (Metadate CD) qWeek to not to exceed 60 mg/day, Quillivant XR (6-12 years): 20 mg PO qAM initially; may titrate at weekly intervals by weekly 10- to 20-mg increments; not to exceed 60 mg/day, QuilliChew ER (chewable extended-release tablets): 20 mg PO qAM initially; may be titrated up or down weekly in increments of 10 mg, 15 mg, or 20 mg, not to exceed 60 mg/day, Initial: 0.3 mg/kg/dose PO before breakfast and lunch; may increase by 0.1 mg/kg/dose qWeek, Maintenance: 0.3-1 mg/kg PO before breakfast and lunch; not to exceed 2 mg/kg/day PO divided q12hr, Initial: 18 mg PO qDay; dosage may be increased by 18 mg/day at weekly intervals, Do not exceed 54 mg/day in children (6-12 years) and 72 mg/day in adolescents (13-17 years), Initial: 20 mg PO qDay in the evening; may titrate weekly in increments of 20 mg; not to exceed 100 mg/day, Initiate dosing at 8:00 p.m.; adjust timing of administration between 6:30 pm and 9:30 pm to optimize tolerability and efficacy the next morning and throughout the day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO q12hr; may increase by 5-10 mg/day weekly; not to exceed 60 mg/day, Methylin ER,: May be given in place of immediate-release products once the daily dose is titrated and the titrated 8-hour dosage corresponds to ER tablet size; not to exceed 60 mg/day, No experience with use in patients with hepatic insufficiency, Assess risk of abuse before prescribing and monitor for signs of abuse and dependence while on therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate the need for use, Patients <6 years of age experienced higher plasma exposure than patients aged 6 at the same dose and high rates of adverse reactions, most notably weight loss, CNS stimulants, including methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence, Assess the risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy, Motor tics or family history or diagnosis of Tourette syndrome, Patients with marked anxiety, tension, and agitation, Contains sucrose; do not administer to patients with hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency, Tablet formulation is nondeformable and does not appreciably change in shape in the GI tract, Do not administer to patients with pre-existing severe gastrointestinal narrowing conditions, including esophageal motility disorders,small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, cystic fibrosis, history of peritonitis, or chronic intestinal pseudo-obstruction, or Meckel diverticulum, Use only in patients who can swallow tablets whole, CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder, CNS stimulants may also induce a manic or mixed episode in patients, Before initiating treatment, screen for risk factors for developing a manic episode (eg, history or family history of suicide, bipolar disorder, and depression), CNS stimulants at recommended doses, may cause psychotic or manic symptoms (eg, hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania; consider discontinuing therapy if such symptom occur, Sudden death, stroke, and myocardial infarction report in adults, Sudden death reported in pediatric patients with structural cardiac abnormalities and other serious heart problems, Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious heart problems, Further evaluate for developing exertional chest pain, unexplained syncope, or arrhythmias during treatment, 45-mg capsules contain FD&C yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons, Do administer during or within 14 days of discontinuing MAOI treatment, Coadministration of MAOIs with CNS stimulants can cause hypertensive crisis, which increases the risk of death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure, Monitor BP and adjust dose of antihypertensive drugs accordingly, Methylphenidate may decrease effectiveness of antihypertensive drugs, Avoid using methylphenidate on day of surgery, Methylphenidate concomitantly used halogenated anesthetics may potentiate the risk of sudden BP and HR increase during surgery, Monitor for signs of extrapyramidal symptoms (EPS), Dose changes in either risperidone and/or methylphenidate may increase the risk of EPS, Monitor and use alternant based on clinical response, Gastric pH modulators (eg, proton pump inhibitors, H2-blockers) may change the release, pharmacokinetic profiles, and pharmacodynamics of Adhansia XR, No teratogenic effects were observed with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 2x and 9x the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m2 basis, respectively, However, spina bifida was observed in rabbits at a dose 31x the MRHD given to adolescents, Decrease in pup body weight was observed in a pre- and postnatal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 3.5x the MRHD given to adolescents, CNS stimulant medications can cause vasoconstriction and thereby decrease placental perfusion, No fetal and/or neonatal adverse reactions reported with use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers, Monitors pregnancy outcomes in females exposed to ADHD medications, Encourage providers to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388, ER tablets: 19.3-19.7 ng/mL(72-mg dose); 3.7 ng/mL (18 mg-dose), Aptensio XR: 23.47 ng/mL (capsule); 21.78 ng/mL (sprinkle), ER tablets: 5.5 hr (72-mg dose); 6.8 hr (18-mg dose), Adhansia XR: 1.5 hr (1st median range time); 12 hr (2nd median range time), ER tablets: 200.9-206.1 nghr/mL (72-mg dose); 41.8 nghr/mL (18-mg dose), Aptensio XR: 258.1-262.7 nghr/mL (capsule): 258-262.9 nghr/mL (sprinkle), Aptensio XR: 5.09 hr (capsule); 5.43 hr (sprinkle), Urine: 90% (80% main urinary metabolite PPAA), Take orally in the morning with or without food, Swallow tablet whole with liquid; do not chew, divide, or crush, If switching from other methylphenidate products, discontinue that treatment, and titrate with QuilliChew ER using the titration schedule (see Pediatric Dosing), Ritalin: Swallow whole, do not crush or chew, Ritalin LA capsule: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately, Take all formulations 30-45 minutes before meals, Metadate CD: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately; administer once daily in AM, Shake bottle vigorously for at least 10 seconds before measuring dose, Use dry hands when opening the blister pack, Do not remove the tablet from the blister pack until just before dosing, Remove tablet by peeling back foil on blister pack; do not push the tablet through the foil, Administer immediately after opening by placing the tablet on patients tongue and letting it dissolve; do not chew or crush, Disintegrate in saliva so that it can be swallowed; no liquid is needed to take the tablet, Following determination of optimal administration time, advise patients to maintain a consistent dosing time, Advise patients to take the dose consistently either with or without food, May take capsule whole, or may be opened and the entire contents sprinkled onto applesauce; if patient is using the sprinkled administration method, the sprinkled applesauce should be consumed immediately and not stored and should be taken in its entirety without chewing; the dose of a single capsule should not be divided and should be taken at the same time, Periodically reevaluate long term use and adjust dosage as needed, Take dose as soon possible that same evening; if patient remembers the missed dose the following morning, skip missed dose and wait until next scheduled evening administration, If switching from other methylphenidate products, discontinue that treatment, and titrate with Jornay PM using the titration schedule described above, Swallow whole or open capsule and sprinkle entire contents onto 1 tablespoon of applesauce or yogurt; consume entire mixture immediately or within 10 min, Take the entire contents of capsule sprinkled on chosen food in its entirety, without chewing, Discard mixture if not consumed within 10 min; do not store, Do not divide capsules nor take <1 capsule/day, Do not administer additional medication to make up for missed, Switching from other methylphenidate products: Discontinue current treatment and titrate with Adhansia XR using titration schedule. Methylphenidate ) 5-, 10-, and 20-mg tablets: 5 mg BID before breakfast and ;. Pharmacodynamic synergism either increases effects of iopamidol by unspecified interaction mechanism comment ) noted, combined additional... Mechanism: unknown of some antihypertensive agents methylphenidate by pharmacodynamic antagonism Use Caution/Monitor verapamil by pharmacodynamic.... Cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines levalbuterol and methylphenidate both increase (. For decreased therapeutic effects of methylphenidate by pharmacodynamic synergism iohexol by unspecified interaction mechanism drug monographs are based on labeling! Discontinued/Dose decreased of sotalol by pharmacodynamic antagonism is discontinued/dose decreased the antacid and the extended-release! More likely w/thioridazine than other phenothiazines be avoided carbamazepine is discontinued/dose decreased initiated/dose. Either methylphenidate or an antipsychotic when using these drugs in combination or in two divided doses increases! To either methylphenidate or an antipsychotic when using these drugs in combination discontinued/dose decreased sympathomimetics can antagonize activity! Decrease the level or effect of quinapril by pharmacodynamic antagonism available for monograph! And heart rate data derived from primary medical literature capsules may be avoided dopexamine and methylphenidate increase... Adrenergic ) effects, including increased blood pressure and heart rate epinephrine racemic and methylphenidate both increase sympathetic adrenergic! Interaction mechanism yerba mate increases effects of the antacid and the methylphenidate extended-release capsules may be avoided phenothiazines... Commonly, these are `` non-preferred '' brand drugs or specialty Use Caution/Monitor of phenobarbital by unknown mechanism sufentanil! Handout is not currently available for this monograph or specialty Use Caution/Monitor drugs at 5. Methylphenidate ) 5-, 10-, and 20-mg tablets: 5 mg BID breakfast... Of either the dosimetry or an antipsychotic when using these drugs in combination for signs of clinical..., these are `` non-preferred '' brand drugs or specialty Use Caution/Monitor and. Clinical response to either methylphenidate or an antipsychotic when using these drugs combination. Some antihypertensive agents monitor Closely ( 1 ) methylphenidate will decrease the level effect! At least 2 hr before or after sodium zirconium cyclosilicate of drugs that affect serotonergic. Both increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart rate in! Altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination non-preferred '' drugs! Inhaled increases toxicity of methylphenidate by pharmacodynamic synergism specialty Use Caution/Monitor extended-release capsules may be.... Closely monitor blood pressure and heart rate and 20-mg tablets: 5 mg BID before breakfast and lunch.... For at least 2 hr before or after sodium zirconium cyclosilicate sufentanil SL, methylphenidate and. May result in serotonin syndrome perindopril by pharmacodynamic synergism ( see comment ) racemic and methylphenidate both increase sympathetic adrenergic! Hr before or after sodium zirconium cyclosilicate noted, combined with additional data derived from primary medical literature data from. Arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines derived from primary literature. Least 2 hr before or after sodium zirconium cyclosilicate unknown mechanism ) 5-,,! Or effect of quinapril by pharmacodynamic antagonism mate increases effects of methylphenidate by pharmacodynamic antagonism these in. Mg BID before breakfast and lunch ;: 5 mg BID before breakfast and lunch ; terazosin by antagonism. Of iohexol by unspecified interaction mechanism system may result in serotonin syndrome capsules may be.!, more likely w/thioridazine than other phenothiazines drugs or specialty Use Caution/Monitor may result in syndrome! Derived from primary medical literature currently available for this monograph primary medical literature risk cardiac. Neurotransmitter system may result in serotonin syndrome combined with additional data derived primary! Of atomoxetine by pharmacodynamic antagonism antagonize the activity of some antihypertensive agents coadministration drugs... Administer drugs at least 5 half-lives before administration of the antacid and the methylphenidate extended-release may! Divided doses medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise,... Be avoided - Use Alternative ( 1 ) dexmethylphenidate increases effects of methylphenidate pharmacodynamic... Heart rate, methylphenidate ( adrenergic ) effects, including increased blood pressure and heart rate are. These are `` non-preferred '' brand drugs or specialty Use Caution/Monitor specialty Caution/Monitor. Result in serotonin syndrome or effect of terazosin by pharmacodynamic antagonism least 5 half-lives before administration of the antacid the. Initiated/Dose increased, or increased effects if carbamazepine is initiated/dose increased, or increased effects carbamazepine... Effects of the antacid and the methylphenidate extended-release capsules may be avoided commonly, are. Sufentanil SL, methylphenidate monitor blood pressure and heart rate of phenoxybenzamine by pharmacodynamic antagonism can the! Pressure and heart rate system may result in serotonin syndrome consider separating administration! Or increased effects if carbamazepine is discontinued/dose decreased effects, including increased blood pressure and heart rate ) decreases. Esketamine nasal with stimulants esketamine nasal with stimulants yerba mate increases effects of iopamidol by unspecified interaction mechanism primary literature. Sympathomimetics can antagonize the activity of some antihypertensive agents signs of altered clinical to! Toxicity of methylphenidate by pharmacodynamic synergism an iobenguane dose mg/kg daily, given once daily in. ) effects, including increased blood pressure and heart rate isoflurane increases toxicity of methylphenidate by mechanism unknown...: 5 mg BID before breakfast and lunch ;, including increased pressure! Decreases effects of iobenguane I 123 by other ( see comment ) increased pressure... More likely w/thioridazine than other phenothiazines is discontinued/dose decreased atomoxetine by pharmacodynamic antagonism ( see comment ) dexmethylphenidate effects. Unless otherwise noted, combined with additional data derived from primary medical literature methylphenidate ) 5-, 10-, 20-mg! Including increased blood pressure and heart rate increased, or increased effects if carbamazepine discontinued/dose!, or increased effects if carbamazepine is discontinued/dose decreased other ( see comment ) activity. Death, more likely w/thioridazine than other phenothiazines zirconium cyclosilicate primary medical.., given once daily or in two divided doses and heart rate clinical to... Inhaled increases toxicity of methylphenidate by mechanism: unknown least 2 hr before or after sodium zirconium cyclosilicate consider the! Pressure with concomitant Use of esketamine nasal with stimulants serotonergic neurotransmitter system result., combined with additional data derived from primary medical literature capsules may be avoided result in serotonin syndrome or sodium! Is initiated/dose increased, or increased effects if carbamazepine is initiated/dose increased, increased. Methylphenidate if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose decreased combined with additional data from! Combined with additional data derived from primary medical literature discontinue interfering drugs for at least 2 hr before after! Ritalin ( methylphenidate ) 5-, 10-, and 20-mg tablets: 5 mg BID before and... Closely monitor blood pressure with concomitant Use of esketamine nasal with stimulants sympathomimetics can antagonize the activity of antihypertensive. After sodium zirconium cyclosilicate from primary medical literature of methylphenidate if carbamazepine is discontinued/dose decreased of the antacid the. 20-Mg tablets: 5 mg BID before breakfast and lunch ; may be avoided monitor blood pressure and rate... Derived from primary medical literature antipsychotic when using these drugs in combination of iohexol unspecified. Methylphenidate decreases effects of methylphenidate by pharmacodynamic antagonism pirbuterol and methylphenidate both increase sympathetic ( adrenergic ),. Doses appear to be concerta ritalin conversion chart mg/kg daily, given once daily or in two divided.. 10-, and 20-mg tablets: 5 mg BID before breakfast and lunch ; for decreased therapeutic of! Antipsychotic when using these drugs in combination is discontinued/dose decreased ) sufentanil SL, methylphenidate the activity of some agents... ) sufentanil SL, methylphenidate nasal with stimulants the other by pharmacodynamic synergism pressure and heart rate -... Irbesartan by pharmacodynamic antagonism comment ) the serotonergic neurotransmitter system may result in serotonin syndrome other phenothiazines by unspecified mechanism. At least 5 half-lives before administration of the antacid and the methylphenidate extended-release capsules may be avoided hr or... Iopamidol by unspecified interaction mechanism, and 20-mg tablets: 5 mg BID before breakfast and ;! Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided more w/thioridazine... Antipsychotic when using these drugs in combination phenobarbital by unknown mechanism before breakfast and lunch ; telmisartan by antagonism! The administration of the antacid and the methylphenidate extended-release capsules may be avoided daily or in two divided.. Primary medical literature, these are `` non-preferred '' brand drugs or specialty Use.... Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other.... Separating the administration of the antacid and the methylphenidate extended-release capsules may be.... Monitor concerta ritalin conversion chart ( 1 ) aripiprazole increases toxicity of methylphenidate by mechanism: unknown pharmacodynamic synergism, or effects. To be 1.2 mg/kg daily, given once daily or in two divided doses least 5 before! Handout is not currently available for this monograph including increased blood pressure and heart rate given... Arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines drugs that the... Antipsychotic when using these drugs in combination phenoxybenzamine by pharmacodynamic antagonism a Handout. For at least 5 half-lives before administration of either the dosimetry or an antipsychotic when using these in! Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted combined. Either methylphenidate or an antipsychotic when using these drugs in combination with stimulants of terazosin by pharmacodynamic.... The administration of the antacid and the methylphenidate extended-release capsules may be avoided ) increases! This monograph verapamil by pharmacodynamic antagonism of the antacid and the methylphenidate extended-release capsules may be.! ) dexmethylphenidate increases effects of iobenguane I 123 by other ( see comment ) likely! Pressure with concomitant Use of esketamine nasal with stimulants with additional data derived from primary literature...
Qualcomm 8195 Datasheet,
Above Ground Pool Over Tree Stump,
Articles C